Trial Profile
To evaluate the effect on cerebral gray matter atrophy in patients with relapsing-remitting multiple sclerosis starting Glatiramer acetate
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 May 2017
Price :
$35
*
At a glance
- Drugs Glatiramer acetate (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors Teva Pharmaceutical Industries
- 06 May 2017 New trial record
- 28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology